DaVita Inc. 2nd Quarter 2026 Results
DaVita Inc. (NYSE: DVA) reported Q2 2026 results for the quarter ended June 30, 2026. Consolidated revenues were $3.554 billion, operating income $579 million, and diluted EPS $4.02. Operating cash flow was $490 million and free cash flow $256 million. The company added a $500 million Term Loan B-2 tranche and repurchased 2.2 million shares at $154.95 average.
How this was made
The 30-second read
Why it matters
Traders can update models for earnings power using the disclosed revenue, operating income, EPS, and cash flow, and reassess near-term risk from leverage changes and the sustainability of treatment growth and cost drivers.
Market read
This is a primary earnings release with hard numbers and capital allocation details, likely driving immediate repricing versus prior expectations.
What to watch
The debt amendment adds leverage via a new $500M term loan tranche, and G&A rose due to professional fees; investors may also scrutinize how much of patient care cost improvement is non-recurring.
Background
DaVita is a US dialysis provider; this PRNewswire release reports Q2 2026 financials for the quarter ended June 30, 2026 and discusses debt, buybacks, and operating metrics.
Ticker impact
DaVita reported Q2 2026 results with $3.554B revenue, $4.02 diluted EPS, and $256M free cash flow, plus a $500M Term Loan B-2 and buybacks.
Moderately positive bias for the next session, with upside capped if investors question sustainability of volume growth and cost drivers.
The release provides multiple concrete datapoints: profitability (operating income, EPS), cash generation (operating and free cash flow), operating metrics (treatments per day up 1.09% QoQ, normalized non-acquired growth 0.3% YoY), and capital actions (incremental $500M term loan and ongoing buybacks).
Market effects
Reinforces demand stability in US dialysis and highlights ongoing cost management and capital structure activity in the dialysis services sector.
Primarily US-focused dialysis metrics, with limited incremental signal for non-US peers beyond integrated-care scale.
International center count and integrated-care spend are disclosed, but the drivers are largely US reimbursement and operating execution.
Counterpoint
Volume growth is modest (normalized non-acquired growth 0.3% YoY), so the EPS and cash flow strength may rely on favorable payor mix and cost timing rather than durable demand acceleration.
Key entities
- companyDaVita Inc.
Reported Q2 2026 results, operating metrics, and capital actions including a $500M incremental Term Loan B-2 and share repurchases.
- personJavier Rodriguez
CEO quoted on patient outcomes and strategic focus for kidney dialysis innovations.
